Jilin Aodong Pharmaceutical Group Co., Ltd. specializes in the manufacturing and marketing of pharmaceutical products. Besides, the group offers food products. Net sales break down by activity as follows: - sale of pharmaceutical products (89.4%); - sale of food products (6.8%); - other (3.8%). All sales are in China.

Employees

5,461

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-07-16	CN¥18.62	-0.21%	20,506,958
26-07-15	CN¥18.66	+4.30%	27,751,556
26-07-14	CN¥17.89	+2.23%	15,633,702
26-07-13	CN¥17.50	-0.79%	12,861,097
26-07-10	CN¥17.64	-1.07%	14,006,300

End-of-day quote Shenzhen S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shenzhen S.E. Other stock markets 2026-07-16			5-day change	1st Jan Change
18.62 ^CNY	-0.21%		+4.43%	-4.66%

06-09	China Approves Aodong Subsidiary's Levocarnitine Injection	MT
05-21	Jilin Aodong Pharmaceutical Gets China Approval for Supplemental Registration of Heart Drug	MT

Market Cap	21.83B 3.22B 2.82B 2.61B 2.39B 4.52B 311B 4.6B 31.07B 12.2B 152B 12.1B 11.84B 524B	P/E 2024	13.1x	P/E 2025	9.57x
Enterprise Value	21.11B 3.12B 2.72B 2.52B 2.31B 4.37B 300B 4.45B 30.04B 11.8B 147B 11.7B 11.44B 506B	EV / Sales 2024	7.76x	EV / Sales 2025	9.49x
Free-Float	67.59%	Yield 2024	2.9%	Yield 2025	2.56%

06-09	China Approves Aodong Subsidiary's Levocarnitine Injection	MT
05-21	Jilin Aodong Pharmaceutical Gets China Approval for Supplemental Registration of Heart Drug	MT
05-12	Jilin Aodong Pharmaceutical Group Co., Ltd. Approves Final Cash Dividend on A Shares for the Year 2025, Payable on 08 July 2026	CI
04-29	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-20	Jilin Aodong Pharmaceutical's Attributable Profit Jumps 54% in 2025	MT
04-17	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-12	Aodong Pharmaceutical's Subsidiary Gets Nod to Market 10 Traditional Chinese Medicines	MT
01-26	Beijing Sun-Novo Pharmaceutical Research Co., Ltd. cancelled the acquisition of Jiangsu Langyan Life Technology Holdings Co., Ltd. from Li Qian, Ganzhou Langyi Investment Center (Limited Partnership) and Other shareholders.	CI
25-10-30	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-21	Aodong Pharmaceutical Gets China Supplementary Nod for Anti-Opioid Medication	MT
25-09-22	Jilin Aodong Pharmaceutical Group Co., Ltd. Approves Interim Cash Dividend on A Shares for 2025, Payable on October 22, 2025	CI
25-09-01	Jilin Aodong Pharmaceutical Group Co., Ltd. Proposes Interim Profit Distribution Plan for 2025	CI
25-08-29	Jilin Aodong Yanbian Pharmaceutical Co., Ltd. announced that it expects to receive CNY 134.393064 million in funding from Jilin Aodong Pharmaceutical Group Co., Ltd.	CI

1 day	-0.21%
1 week	+4.43%
Current month	+5.02%
1 month	+4.14%
3 months	+1.25%
6 months	-7.32%
Current year	-4.66%

Jilin Aodong Pharmaceutical Group Co., Ltd. Stock

Stocks

000623

CNE000000719

Pharmaceuticals

Valuation: Jilin Aodong Pharmaceutical Group Co., Ltd.

Chart: Jilin Aodong Pharmaceutical Group Co., Ltd.

Latest news : Jilin Aodong Pharmaceutical Group Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Jilin Aodong Pharmaceutical Group Co., Ltd.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	17.27	18.77
1 month	17.08	18.88
Current year	16.36	20.93
1 year	16.36	22.08
3 years	12.49	22.08
5 years	12.49	22.08
10 years	12.49	29.43

Manager	Title	Age	Since
Shu Qin Guo CEO	Chief Executive Officer	63	2017-07-16
Kai Yang DFI	Director of Finance/CFO	49	2004-04-30
Shu Yuan Zhang DFI	Director of Finance/CFO	54	2007-06-17

Director	Title	Age	Since
Shu Qin Guo BRD	Director/Board Member	63	2000-01-31
Yu Ju Sun BRD	Director/Board Member	54	2008-05-05
Shu Yuan Zhang BRD	Director/Board Member	54	2020-07-16

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/25/25	An Ning Li	Buy		100	0.0000%
7/29/24	Xiu Lin Li	Buy	Chairman	350,000	0.0302%
7/29/24	Shu Qin Guo	Buy	Chief Executive Officer	320,000	0.0276%

	2024	2025
Net sales	2.61B 385M 337M 312M 286M 541M 37.14B 550M 3.72B 1.46B 18.13B 1.45B 1.42B 62.61B	2.34B 345M 301M 279M 256M 484M 33.22B 492M 3.32B 1.31B 16.22B 1.29B 1.27B 56B
Net income	1.55B 229M 200M 185M 170M 322M 22.07B 327M 2.21B 867M 10.78B 860M 841M 37.21B	2.4B 354M 309M 286M 262M 496M 34.07B 505M 3.41B 1.34B 16.64B 1.33B 1.3B 57.44B
Net Debt	-386M -56.98M -49.8M -46.06M -42.27M -79.99M -5.49B -81.38M -549M -216M -2.68B -214M -209M -9.26B	-724M -107M -93.42M -86.4M -79.28M -150M -10.3B -153M -1.03B -405M -5.03B -401M -393M -17.36B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JILIN AODONG PHARMACEUTICAL GROUP CO., LTD.	-0.21%	+4.43%	+2.65%	+15.01%	3.22B
ELI LILLY AND COMPANY	+1.08%	-3.93%	+48.03%	+160.13%	1,043B
JOHNSON & JOHNSON	+1.19%	-3.52%	+51.70%	+56.36%	602B
ABBVIE INC.	+4.21%	+1.79%	+33.48%	+87.04%	449B
ROCHE HOLDING AG	+0.06%	-1.49%	+29.03%	+23.64%	327B
NOVARTIS AG	+0.88%	+0.05%	+33.21%	+46.42%	279B
ASTRAZENECA PLC	-0.65%	-2.38%	+21.49%	+22.82%	264B
AMGEN INC.	+3.70%	+2.19%	+24.27%	+63.38%	201B
GILEAD SCIENCES, INC.	+3.49%	+1.08%	+24.08%	+76.58%	169B
PFIZER INC.	+1.29%	+3.67%	+2.15%	-30.78%	143B
Average	+1.24%	-0.06%	+27.01%	+52.06%	348.03B
Weighted average by Cap.	+1.55%	-1.81%	+37.33%	+82.75%